Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.61 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.56 |
| ▸ | SELP | P16109 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14685796 | 1.00 | GLP1R (0.61) | GLP1RNOD1SELPFOLH1KMT2A | |
| SCHEMBL13973930 | 1.00 | GLP1R (0.61) | GLP1RNOD1SELPFOLH1KMT2A | |
| SCHEMBL13073574 | 1.00 | GLP1R (0.61) | GLP1RNOD1SELPFOLH1KMT2A | |
| SCHEMBL91017 | 1.00 | GLP1R (0.61) | GLP1RNOD1SELPFOLH1KMT2A | |
| SCHEMBL73399 | 1.00 | GLP1R (0.61) | GLP1RNOD1SELPFOLH1KMT2A | |
| SCHEMBL15002730 | 1.00 | GLP1R (0.61) | GLP1RNOD1SELPFOLH1KMT2A | |
| SCHEMBL13165209 | 1.00 | GLP1R (0.61) | GLP1RNOD1SELPFOLH1KMT2A | |
| SCHEMBL14819870 | 1.00 | GLP1R (0.61) | GLP1RNOD1SELPFOLH1KMT2A | |
| SCHEMBL24390382 | 0.98 | GLP1R (0.65) | GLP1RNOD1SELPFOLH1 | |
| SCHEMBL18626065 | 0.98 | GLP1R (0.65) | GLP1RNOD1SELPFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695226-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-07-04 | — | — | US | disclosed |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2014-04-17 | — | — | US | disclosed |
| US-8536122-B2 | Acylated GLP-1 compounds | NOVO NORDISK A/S (DK) | 2013-09-17 | — | — | US | disclosed |
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120295847-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | GHRHR, SHBG, GHSR | GLP1R 99/4885NOD1 4656/4885SELP 2895/4885 |
| US-20120295847-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | GLP1R 1/4885NOD1 1340/4885SELP 1274/4885 |
| US-20140107324-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | GLP1R 101/4885NOD1 4722/4885SELP 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.